Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT01922752 |
| Title | To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Teva Branded Pharmaceutical Products, R&D Inc |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Teva Investigational Site 10689 | Chicago | Illinois | United States | Details | ||
| Teva Investigational Site 10687 | Philadelphia | Pennsylvania | United States | Details | ||
| Teva Investigational Site 10686 | San Antonio | Texas | United States | Details |